Compare Biogen Inc (BIIB) vs Okta, Inc. (OKTA) Price & Performance

Biogen IncTrade

Okta, Inc.Trade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Okta, Inc. — how do they compare? Biogen Inc trades at $190.26 (market cap $30.86B), while Okta, Inc. trades at $154.5 (market cap $24.25B). The key difference: Biogen Inc is the larger of the two by market cap, and Okta, Inc. is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.

	BIIB	OKTA
Market Cap	$30.86B	$24.25B
Sector	Health	Technology
52-Week High	$216.63	$154.62
52-Week Low	$122.68	$62.93
Enterprise Value	$33.14B	$22.07B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BIIB

Real-world study shows 83% of early Alzheimer's patients stable or improved on LEQEMBI over 17 monthsPRNewsWire · 20 hours agoBullish Biogen's diranersen shows promising Phase 2 results slowing early Alzheimer's decline and reducing tau protein.GlobeNewsWire · 22 hours agoBullish FDA approves LEQEMBI IQLIK, first at-home weekly injection for early Alzheimer's treatmentPRNewsWire · 1 day agoBullish View details →

OKTA

Cybersecurity stocks jump as IBM flags rising cyber fears and spending shifts amid AI concernsCNBC · 16 hours agoBullish View details →

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

About Okta, Inc.

Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.